Welcome to our dedicated page for ZyVersa Therapeutics SEC filings (Ticker: ZVSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ZyVersa Therapeutics filings document the public-company record for a clinical-stage biopharmaceutical issuer whose common stock is quoted on the OTCQB Venture Market under ZVSA. Recent reports cover material agreements, securities purchase arrangements, convertible promissory notes, common stock purchase warrants and other capital-structure disclosures tied to company financing.
The filing record also includes Form 8-K disclosures for financial results, officer and director departures, Nasdaq delisting notices and Form 25 removal from listing and registration. Periodic-report notices and related exhibits document reporting status, governance matters and the company’s formal disclosure obligations.
ZyVersa Therapeutics, Inc. (ZVSA) submitted a Form 25 notice indicating removal of its securities from listing and/or registration on the Nasdaq Stock Market LLC. The filing identifies the issuer's principal office in Weston, Florida, and provides a contact telephone number. The form lists the regulatory provisions for voluntary or exchange-initiated delisting under 17 CFR 240.12d2-2 and certifies Nasdaq's compliance with the rule for striking the class from listing and/or registration.
ZyVersa Therapeutics, Inc. reports that the Nasdaq Stock Market plans to delist its common stock following the filing of a Form 25 with the SEC on or about September 18, 2025. The delisting will become effective ten days after the Form 25 is filed under Exchange Act Rule 12d2-2.
The company’s common stock was suspended from trading on The Nasdaq Capital Market on July 17, 2025 after failing to regain compliance with Nasdaq’s minimum bid price requirement, and it has been trading on the OTCQB Venture Market under the symbol “ZVSA” since July 28, 2025. ZyVersa states that its common stock will continue trading on the OTCQB without disruption.